Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Hematopoietic stem cell transplantation: up-date from ASH 2016

Hematopoietic stem cell transplantation: up-date from ASH 2016 Allogeneic hematopoietic stem cell transplantation (allo HSCT) offers a potentially curative approach for acute myeloid leukemia (AML) with intermediate or adverse risk according to the recently published European Leukemia Network (ELN) guidelines. As outcome might be reduced by graft-versus-host disease (GvHD) or infectious complications, tools for early detection of GvHD are warranted. In contrast, autologous stem cell transplantation (ASCT) represents a relatively safe therapeutic approach. However, further improvement can be observed by the introduction of maintenance therapy after single ASCT, e. g., with lenalidomide or rituximab. http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png memo - Magazine of European Medical Oncology Springer Journals

Hematopoietic stem cell transplantation: up-date from ASH 2016

Download PDF
4 pages

Loading next page...
 
/lp/springer-journals/hematopoietic-stem-cell-transplantation-up-date-from-ash-2016-l0wY5c2AWB
Publisher
Springer Journals
Copyright
Copyright © 2017 by Springer-Verlag Wien
Subject
Medicine & Public Health; Oncology; Medicine/Public Health, general
ISSN
1865-5041
eISSN
1865-5076
DOI
10.1007/s12254-017-0337-1
Publisher site
See Article on Publisher Site

Abstract

Allogeneic hematopoietic stem cell transplantation (allo HSCT) offers a potentially curative approach for acute myeloid leukemia (AML) with intermediate or adverse risk according to the recently published European Leukemia Network (ELN) guidelines. As outcome might be reduced by graft-versus-host disease (GvHD) or infectious complications, tools for early detection of GvHD are warranted. In contrast, autologous stem cell transplantation (ASCT) represents a relatively safe therapeutic approach. However, further improvement can be observed by the introduction of maintenance therapy after single ASCT, e. g., with lenalidomide or rituximab.

Journal

memo - Magazine of European Medical Oncology – Springer Journals

Published: Jun 1, 2017

References

  • Hematopoietic stem cell transplantation for patients with AML in first complete remission
    Cornelissen, JJ; Blaise, D
  • Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel
    Dohner, H; Estey, E; Grimwade, D; Amadori, S; Appelbaum, FR; Buchner, T
  • Results of a HOVON/SAKK donor versus no-donor analysis of myeloablative HLA-identical sibling stem cell transplantation in first remission acute myeloid leukemia in young and middle-aged adults: benefits for whom?
    Cornelissen, JJ; Putten, WL; Verdonck, LF; Theobald, M; Jacky, E; Daenen, SM
  • Allogeneic stem cell transplantation for acute myeloid leukemia in first complete remission: systematic review and meta-analysis of prospective clinical trials
    Koreth, J; Schlenk, R; Kopecky, KJ; Honda, S; Sierra, J; Djulbegovic, BJ
  • The pathophysiology of acute graft-versus-host disease
    Jaksch, M; Mattsson, J
  • A prognostic score for acute graft-versus-host disease based on biomarkers: a multicentre study
    Levine, JE; Braun, TM; Harris, AC; Holler, E; Taylor, A; Miller, H
  • An early biomarker algorithm predicts lethal graft-versus-host disease and survival after allogeneic hematopoietic cell transplantation
    Hartwell, M; Ozbek, U; Holler, E; Renteria, A; Reddy, P; Aziz, M
  • Ruxolitinib in corticosteroid-refractory graft-versus-host disease after allogeneic stem cell transplantation: a multicenter survey
    Zeiser, R; Burchert, A; Lengerke, C; Verbeek, M; Maas-Bauer, K; Metzelder, SK
  • Multicenter open-label phase 2 study of ibrutinib in chronic graft versus host disease (cGVHD) after failure of corticosteroids
    Miklos, D; Cutler, S; Arora, M; Waller, EK; Jagasia, M; Pusic, I
  • Post-remission treatment with allogeneic stem cell transplantation in patients aged 60 years and older with acute myeloid leukaemia: a time-dependent analysis
    Versluis, J; Hazenberg, CL; Passweg, JR; Putten, WL; Maertens, J; Biemond, BJ
  • Reduced-intensity conditioning versus standard conditioning before allogeneic haemopoietic cell transplantation in patients with acute myeloid leukaemia in first complete remission: a prospective, open-label randomised phase 3 trial
    Bornhauser, M; Kienast, J; Trenschel, R; Burchert, A; Hegenbart, U; Stadler, M
  • Results of a phase III randomized, multi-center study of allogeneic stem cell transplantation after high versus reduced intensity conditioning in patients with Myelodysplastic Syndrome (MDS) or acute Myeloid Leukemia (AML): blood and marrow transplant clinical trials network
    Scott, BLP; Logan, B; Wu, J; Devine, S; Porter, DL; Maziarz, RT
  • Fludarabine and Busulfan plus low dose TBI versus cyclophosphamide plus TBI in allogeneic hematopoietic cell transplantation for adult acute lymphoblastic leukemia: equivalent outcomes in a recent, large Canadian multicenter cohort
    Speziali, C; Daly, A; Abuhaleeqa, M; Nitta, J; Mourad, J; Seftel, M
  • Management of cytomegalovirus infection in haemopoietic stem cell transplantation
    Emery, V; Zuckerman, M; Jackson, G; Aitken, C; Osman, H; Pagliuca, A
  • Transfer of minimally manipulated CMV-specific T cells from stem cell or third-party donors to treat CMV infection after alloHSCT
    Neuenhahn, M; Albrecht, J; Odendahl, M; Schlott, F; Dossinger, G; Schiemann, M
  • Prevention of viral infections after T cell depleted allogeneic stem cell transplantation by infusion of multi-antigen specific T cell products
    Roex, MC; Balen, P; Hageman, L; Egmond, E; Veld, S; Hoogstraten, C
  • Management of veno-occlusive disease: the multidisciplinary approach to care
    Wallhult, E; Kenyon, M; Liptrott, S; Mank, A; Ni Chonghaile, M; Babic, A
  • Stratification of allogeneic hematopoietic cell transplant by risk of developing veno-occlusive disease: a model for assigning a risk score
    Strouse, C; Zhan, Y; Zhang, MJ; DiGilio, A; Pasquini, MC; Horowitz, M
  • Sustained remissions following chimeric antigen receptor modified T cells directed against CD19 (CTL019) in patients with relapsed or refractory CD19+ lymphomas
    Schuster, S; Svoboda, J; Nasta, S; Porter, DE; Chong, EA; Landsburg, DJ
  • Kte-C19 (anti-CD19 CAR T cells) induces complete remissions in patients with refractory diffuse large B‑cell Lymphoma (DLBCL): results from the pivotal phase 2 ZUMA-1
    Neelapu, S; Locke, FL; Bartlett, NL; Lekakis, L; Miklos, D; Jacobson, CA
  • EBV-specific donor cells transduced to express a high-affinity WT1 TCR can prevent recurrence in post-HCT patients with high-risk AML
    Chapuis, A; Egan, D; Bar, B; Schmitt, TM; McAfee, M; Perdicchio, M
  • Comparison of Autologous Hematopoietic Cell Transplant (autoHCT), Bortezomib, Lenalidomide (Len) and Dexamethasone (RVD) Consolidation with Len Maintenance (ACM), Tandem Autohct with Len Maintenance (TAM) and Autohct with Len Maintenance (AM) for up-Front Treatment of Patients with Multiple Myeloma (MM): Primary Results from the Randomized Phase III Trial of the Blood and Marrow Transplant Clinical Trials Network (BMT CTN 0702 – StaMINA Trial)
    Stadtmauer, M; Pasquini, M; Blackwell, B; Knust, K; Bashey, A; Devine, S
  • Rituximab maintenance after autologous stem cell transplantation prolongs survival in younger patients with mantle cell lymphoma: final results of the randomized phase 3 Lyma trial of the Lysa/Goelams group
    Gouill, SS; Thieblemont, C; Oberic, L; Moreau, A; Bouabdallah, K; Gyan, E
  • Treatment of relapse after allogeneic stem cell transplantation in children and adolescents with ALL: the Frankfurt experience
    Willasch, AM; Salzmann-Manrique, E; Krenn, T; Duerken, M; Faber, J; Opper, J
  • Biomarker panel for chronic graft-versus-host disease
    Yu, J; Storer, BE; Kushekhar, K; Abu, ZM; Zhang, Q; Gafken, PR